Episode 5

Why More Mitochondrial DNA Mutations Can Mean a Better Outcome - Dr Ilaria Pagani

This episode explores how chronic myeloid leukemia has been transformed by imatinib and other TKIs, while also showing why major clinical challenges remain for the patients who do not respond well or want to stop therapy. Host Scientific Editor Dr Charles de Bock talks with Dr. Ilaria Pagani about her recent HemaSphere paper on mitochondrial DNA mutations, oxidative phosphorylation, and treatment response in CML, and why mitochondria may be an overlooked source of biomarkers and new targets. We discuss the biology of relapse, why some patients can achieve treatment-free remission, and how mitochondrial metabolism may help explain differences between poor responders and super responders. The conversation also touches on patient advocacy, quality of life, and the need for more collaborative, metabolism-focused research.

Read the article in full, open access: https://hsphere.pub/448

You've read the paper, now hear the story.

About the Podcast

Show artwork for HemaSphere Podcast
HemaSphere Podcast
The HemaSphere Podcast focuses on casual and insightful discussions about select HemaSphere publications and hematology research. Listen to the stories behind the papers.

About your hosts

Profile picture for HemaSphere Journal

HemaSphere Journal

Listen and enjoy casual, insightful discussions about #hematology research.
Profile picture for European Hematology Association

European Hematology Association

The European Hematology Association promotes excellence in patient care, research, and education in hematology. We serve medical professionals, researchers, and scientists with an active interest in hematology. We are proud to be the largest European-based organization connecting hematologists worldwide to support career development and research, harmonize hematology education, and advocate for hematologists and hematology